Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 13/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550266 | 0.85 | TSHR (0.60) | VCAM1ALDH1A1TSHRTDP1MAPK1 | |
| SCHEMBL10891021 | 0.83 | VCAM1 (0.51) | VCAM1ALDH1A1KDM4EPOLBKDM1A | |
| SCHEMBL27311122 | 0.83 | VCAM1 (0.51) | VCAM1ALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL213965 | 0.83 | VCAM1 (0.56) | VCAM1ALDH1A1KDM4EPOLBKDM1A | |
| SCHEMBL29707970 | 0.83 | VCAM1 (0.56) | VCAM1ALDH1A1KDM4EPOLBKDM1A | |
| SCHEMBL627966 | 0.83 | VCAM1 (0.51) | VCAM1ALDH1A1KDM4EPOLBKDM1A | |
| SCHEMBL811582 | 0.83 | VCAM1 (0.54) | VCAM1ALDH1A1KDM4EPOLB | |
| SCHEMBL18653119 | 0.83 | VCAM1 (0.51) | VCAM1ALDH1A1KDM4EPOLBKDM1A | |
| SCHEMBL671271 | 0.83 | VCAM1 (0.54) | VCAM1ALDH1A1KDM4EPOLBKDM1A | |
| SCHEMBL1983738 | 0.81 | VCAM1 (0.59) | VCAM1ALDH1A1KDM4EPOLBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0128563-B1 | IMPROVED ANTIFOGGANT PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-04-04 | — | — | EP | claimed |
| EP-0128563-A2 | Improved antifoggant process | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-12-19 | — | — | EP | claimed |
| US-4468454-A | NEGATIVE SILVER HALIDE EMULSIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-28 | — | — | US | claimed |
| EP-0045570-B1 | USE OF ORGANIC HALOGEN COMPOUNDS TO REDUCE OR PREVENT FOG IN NEGATIVE-WORKING SILVER HALIDE EMULSIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-09-28 | — | — | EP | claimed |
| US-4323645-A | Organic halogen compounds for negative-working silver halide emulsions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-04-06 | — | — | US | claimed |
| EP-0045570-A1 | Use of organic halogen compounds to reduce or prevent fog in negative-working silver halide emulsions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-02-10 | — | — | EP | claimed |
| US-8501931-B2 | Convertible nucleoside derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-08-06 | — | — | US | disclosed |
| US-20090030039-A1 | Piperidine Derivatives as Cxcr3 Receptor Antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-01-29 | — | — | US | disclosed |
| EP-1984349-A1 | PIPERIDINE DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090826-A1 | PIPERIDINE DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
| US-7189864-B2 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20060247244-A1 | Quinoxalinones and their use especially in the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | US | disclosed |
| US-6974876-B2 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-12-13 | — | — | US | disclosed |
| EP-0045570-A1 | Use of organic halogen compounds to reduce or prevent fog in negative-working silver halide emulsions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-02-10 | — | — | EP | disclosed |
| US-4243806-A | ANTIALLERGENS; ANTIHISTAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-01-06 | — | — | US | disclosed |
| US-4215219-A | CHELATING AGENTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1980-07-29 | — | — | US | disclosed |
| US-4208430-A | CARBAMIMIDOTHIOIC ACID PHENYLALKYL ESTERS | SMITHKLINE CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
| US-4179505-A | ANTIALLERGENS; ANTIHISTAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-4085261-A | CHELATING AGENT WITH A STYRENE POLYMER BACKBONE | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-04-18 | — | — | US | disclosed |
| US-4018790-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030039-A1 | Piperidine Derivatives as Cxcr3 Receptor Antagonists | CXCR3, CXCR1, CXCR2 | VCAM1 479/4885ALDH1A1 1281/4885KDM4E 2786/4885 |
| US-20060247244-A1 | Quinoxalinones and their use especially in the treatment of cardiovascular diseases | NQO2, NQO1, XDH | VCAM1 1060/4885ALDH1A1 647/4885KDM4E 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.